Oncology practices operate on razor-thin margins while managing some of the most complex claims in healthcare. High-cost infused and oral drugs, combination regimens, frequent prior authorizations, and rapid payer policy changes all collide inside your revenue cycle. If your outsourced billing partner is not performing at the right level, you do not simply see “a few more denials.” You see gaps measured in hundreds of thousands of dollars, delayed cash, and stressed front-line staff.
Yet most practices still evaluate billing vendors using shallow metrics such as “monthly collections” or call center responsiveness. These are not enough. To know whether you are truly working with one of the best oncology billing companies, you must track performance at the level of accounts receivable (AR), denials, coding and documentation, and appeal execution, and you must tie those metrics to operational workflows.
This article lays out a structured, oncology-specific evaluation framework that RCM leaders, administrators, and practice owners can use to benchmark current vendors or compare new ones.
Anchor Your Evaluation on AR Performance, Not Just Top-Line Collections
Collections alone can hide structural problems. A vendor might appear to be “doing fine” because money is coming in, but aging claims, rising write-offs, and growing patient balances tell a different story. In oncology, where a single chemotherapy episode can exceed 10,000 dollars, AR discipline is the difference between stable cash flow and recurring crises.
When assessing oncology billing companies, anchor your evaluation around a small set of AR-centric KPIs and how the vendor manages them operationally.
Key AR Metrics and Benchmarks
- Days in AR (A/R days): For a mature oncology practice, a target of 30 to 40 days is realistic, depending on payer mix and case complexity. Consistently above 45 days is a warning sign that claims are not being moved to resolution quickly enough.
- Percentage of AR over 90 days: In a high-performing oncology environment this should be under 15 percent. When more than 20 percent of AR sits in the 90-plus bucket, you likely have systemic follow-up issues, inadequate escalation, or unresolved root causes in front-end processes.
- Net collection rate (NCR): For oncology, where contractuals and clinical editing can be complex, aim for 95 percent or higher. Anything below 92 to 93 percent suggests avoidable leakage.
Ask each vendor to provide these metrics for your practice, segmented by:
- Payer (Medicare, commercial, Medicaid, specialty pharmacy)
- Service category (infusion, radiation, E/M, procedures, oral oncolytics)
- Place of service (hospital outpatient, physician office, infusion center)
If they cannot produce this segmentation, it is unlikely they are actively managing AR at the level required for oncology.
Operational Questions to Ask
- How often does your team touch unpaid oncology claims by age bucket (for example 0–30, 31–60, 61–90, 91-plus)?
- What are your escalation rules when a high-dollar oncology drug claim hits 30, 45, and 60 days?
- How do you separate “slow-paying but collectible” from “truly uncollectible” in oncology?
Look for vendors that can explain their workflow in operational detail, not just repeat that they “work AR every day.” In oncology, structured AR governance is a prerequisite to financial stability.
Scrutinize First-Pass Denials and Root-Cause Prevention
Denials are more than a back-end problem. In oncology, a high first-pass denial rate usually reflects broken prior authorization workflows, incorrect drug coding, missing compendia support, or incomplete documentation at the point of care. A best-in-class oncology billing company treats denials as a quality signal and designs prevention strategies, not just rework queues.
Denial Metrics That Should Be Non-Negotiable
- First-pass denial rate: A general industry benchmark is under 5 to 7 percent of claims denied on first submission. Because oncology is complex, some practices accept higher rates, but a strong partner will aggressively drive toward that range.
- Denials per 100 claims for key service lines: Especially:
- High-cost infused drugs (e.g., J-codes for immunotherapies, monoclonal antibodies)
- Radiation therapy episodes
- Complex E/M with prolonged services or same-day chemo administration
- Denial write-off rate: Percent of denied charges ultimately written off as uncollectible (excluding true charity or non-covered services). This should be tightly monitored and trending downward.
Root-Cause Analysis and Prevention Framework
A capable oncology vendor should be able to walk you through a denial management framework that looks something like this:
- Classify denials by type (authorization, medical necessity, coding, eligibility, timely filing, bundling).
- Quantify revenue at risk by denial type and by drug or regimen.
- Trace denial back to the workflow step:
- Order entry and diagnosis selection
- Authorization and benefit verification
- Charge capture and coding
- Claim scrubbing and submission
- Redesign upstream controls: for example, build payer-specific authorization checklists for each regimen, implement mandatory diagnosis mapping rules, or use system edits that block known incorrect drug–diagnosis combinations.
When evaluating vendors, request a recent denial analysis they completed for another oncology client (with identifying data removed) and ask what prevention changes resulted. If they cannot produce one, or it looks generic across specialties, they are unlikely to be operating at the level your practice needs.
Evaluate Appeals Strategy, Timeliness, and Win Rate
Many oncology denials are recoverable, but only if the vendor has the expertise and urgency to pursue them within payer timelines. Appeals for high-cost oncology drugs require precise documentation, familiarity with payer medical policies, and consistent follow-up. This is where cash leaks can silently accumulate.
Appeals KPIs to Demand
- Average time from denial to appeal submission: A strong standard is within 7 to 10 business days. Longer delays increase the risk of missing appeal windows and signal poor queue management.
- Appeal success rate: Percentage of appealed oncology denials that are overturned, at least partially. A robust partner should provide this rate by:
- Payer
- Denial reason (for example medical necessity vs. authorization vs. coding)
- Service type or drug
- Recovered dollars per appeal: Not every denial is equal. You want to see clear focus on high-dollar oncology drugs and complex episodes, not just easy low-dollar fixes.
Operational Components of a Strong Oncology Appeals Program
Ask detailed questions about how they execute appeals for oncology-specific issues:
- Do you use oncology-trained nurses or coders to prepare medical necessity appeals for off-label or complex regimens?
- How do you incorporate compendia support (for example NCCN) and trial data in appeal letters when policies are ambiguous?
- What templates and checklists do you use to ensure all supporting documents (clinic notes, chemo flowsheets, pathology, imaging, authorization approvals) are included?
- How do you track payer-level policy changes that affect appeal strategy for cancer drugs or radiation therapy?
A best oncology billing company will have a dedicated clinical or high-complexity denials team, standardized appeal letter templates for different payers, and a work queue structure that prioritizes high-value, time-sensitive denials. They should also be able to show you trend reports demonstrating improved appeal success over time.
Assess Coding, Charge Capture, and Documentation Alignment with Oncology Care
Even with clean authorizations and fast follow-up, you will lose revenue if coding and documentation do not correctly reflect the complexity of oncology care. Documentation gaps are particularly dangerous when payers increase medical necessity scrutiny for expensive therapies.
Key Focus Areas in Oncology Coding and Charge Capture
- Drug coding accuracy:
- Correct HCPCS codes and units for infused and injectable drugs
- Appropriate use of waste modifiers (for example JW and JZ) where applicable
- Accurate NDC capture and linkage to HCPCS codes when required by payer
- E/M and visit coding:
- Accurate level selection, especially for complex regimens and multi-problem visits
- Appropriate use of prolonged services codes where documentation supports it
- Procedure and radiation therapy coding: Correct bundling and sequencing for simulation, treatment planning, and delivery.
- Diagnosis coding: Alignment of ICD-10 codes with staging, biomarkers, and treatment intent, which can drive payer coverage and utilization management triggers.
How to Test a Vendor’s Oncology Coding Maturity
As part of your evaluation, consider a focused coding and documentation review:
- Provide a sample of de-identified chemo and immunotherapy encounters, including notes and flowsheets.
- Ask the vendor’s coding team to:
- Assign codes and units
- Identify missing documentation needed for defensible billing
- Flag potential upcoding or downcoding risks
- Compare their coding to your current process and to external best-practice guidelines where available.
A strong partner will also propose proactive documentation improvement initiatives, such as standardized templates for oncologists that capture staging, performance status, treatment intent, and response. These details support both payment and compliance, especially when payers perform targeted reviews of oncology regimens.
Interrogate Front-End Workflows: Eligibility, Benefits, and Prior Authorization
For oncology, front-end revenue cycle performance often determines how many denials you will see downstream. Eligibility missteps, incomplete benefit checks for oral agents and home infusions, and weak prior authorization workflows can each generate avoidable rework and unrecoverable denials.
Front-End Metrics That Predict Denial Risk
- Eligibility verification rate: Percentage of scheduled oncology patients whose eligibility and benefits are verified prior to service. For high-end infusion centers this should be extremely close to 100 percent.
- Authorization capture rate: Percentage of services requiring prior authorization that have approvals on file before treatment begins. Oncology practices should demand near-perfect rates for high-cost regimens and radiotherapy.
- Authorization-related denial rate: Track how many denials cite missing, invalid, or expired authorizations. This should trend toward zero once robust workflows are in place.
Workflow Design Questions for Vendors
When evaluating a billing partner, ask specifically how they manage oncology front-end tasks:
- How far in advance do you initiate authorizations for new regimens and dose changes?
- Do you maintain payer- and drug-specific authorization matrices that specify documentation requirements, trial data, and step therapy expectations?
- How do you manage authorization renewals for ongoing regimens and transitions between lines of therapy?
- How are benefit details for specialty pharmacy, oral oncolytics, and home health or infusion coordinated with the practice so that financial counseling and patient responsibility discussions are accurate?
A top-tier oncology billing company will have dedicated front-end teams staffed and trained around oncology authorization patterns. They will also collaborate with your clinic scheduling and nursing staff so that no patient is treated without clarity around coverage risks.
Demand Transparency, Reporting, and Governance That You Can Actually Run the Business On
Even if a billing company is technically competent, they may still fail your organization if reporting is opaque or difficult to interpret. Oncology service lines are expensive to run. You need granular, timely, and oncology-specific reports to manage payer strategy, contract negotiations, staffing, and drug inventory decisions.
Reporting and Governance Essentials
A vendor positioned as a “best oncology billing company” should deliver:
- Standard oncology RCM dashboard including:
- AR days and aging by payer and service line
- Denials and write-offs by reason and drug
- Authorization-related denials and resolution rates
- Net collection rate and bad debt trends
- Drill-down capability:
- Ability to move from summary metrics to underlying claims within a few clicks or via regular exports
- Clear tagging of high-cost drugs and regimens so expensive issues are never buried
- Governance cadence:
- Monthly or quarterly joint reviews focused on performance gaps and root-cause interventions
- Documented action plans with owners and timelines for each major issue (for example new payer edit for a specific regimen, or recurring registration error in one location)
Ask to see sample dashboards from other oncology clients, again with data masked. Evaluate whether they provide the level of detail you would need to make decisions about staffing, drug purchasing, payer negotiations, and clinic scheduling. If the reporting looks like a generic multi-specialty template, the vendor may not be sufficiently tailored to oncology.
Build a Practical Scorecard to Compare Oncology Billing Companies
Once you understand the metrics and workflows that matter, you can translate them into a practical vendor evaluation scorecard. This helps avoid selection based on sales presentations and instead grounds your decision in measurable criteria.
Suggested Scorecard Domains
Consider scoring each prospective or current vendor across the following domains, using a simple 1 to 5 scale where 1 is unacceptable and 5 is best in class:
- AR and cash flow performance
- AR days, AR over 90 days, net collection rate, transparency into high-dollar inventory
- Denial prevention and management
- First-pass denial rate, root-cause analysis capability, denial write-off rates for oncology drugs
- Appeals strength
- Timeliness, success rate, depth of clinical and policy knowledge in oncology
- Coding and documentation
- Accuracy in drug units and modifiers, ICD-10 specificity, proactive documentation improvement
- Front-end operations
- Eligibility and benefit verification, prior authorization processes, coordination with clinic teams
- Reporting and governance
- Granularity of oncology-specific reporting, joint review cadence, responsiveness to issues
Use hard data, sample reports, case studies, and pilot results where possible to inform each score. Practices that take this disciplined approach often discover that a vendor which appeared “fine” on surface metrics is actually underperforming when viewed through an oncology-specific lens.
Driving Financial Stability and Choosing Your Next Step
A structured best oncology billing companies evaluation is not just an exercise in vendor management. It is a tool for protecting cash flow, reducing staff burnout from constant rework, and maintaining patient access to complex therapies. When you measure AR, denials, appeals, coding, and front-end performance in an oncology-specific way, you create a clear picture of whether your current partner is a strategic asset or a hidden liability.
If your analysis reveals chronic issues such as AR days above 45, rising drug-related denials, weak appeal win rates, or limited reporting transparency, it may be time to demand a corrective action plan or explore a new partner with deeper oncology expertise.
If you would like an external perspective on your current RCM performance, or support in building an oncology-specific evaluation scorecard, you can contact our team. We work with practices and health systems to benchmark their oncology revenue cycle, identify avoidable leakage, and design sustainable workflows that stabilize cash and support clinical growth.
References
Healthcare Financial Management Association. (n.d.). Key healthcare financial metrics. Retrieved from https://www.hfma.org
National Comprehensive Cancer Network. (n.d.). NCCN clinical practice guidelines in oncology. Retrieved from https://www.nccn.org
Office of Inspector General. (2023). Medicare payments for Part B drugs in oncology. Retrieved from https://oig.hhs.gov
